The collaboration is expected to include development of thermostable solid-dose needle-free vaccines for a variety of infectious diseases and evaluation of the potential to generate improved vaccine responses with simplified administration and reduced storage and distribution costs.

GeoVax’s vaccine technology is based on its patented Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform, which generates noninfectious VLPs in the individual being vaccinated. This technology mimics a natural viral infection, triggering the body to produce a robust and durable immune response (the way that vaccines protect against diseases), typically with only a single dose required for desired protection. As a result, the GeoVax vaccines provide the opportunity to deliver a more efficient, lower cost, highly effective vaccine.

Enesi’s proprietary ImplaVax® solid-dose formulation and needle-free device technology comprises three main components: a single precision-engineered solid-dose Universal Vaccine Implant (UVI) containing the vaccine construct, a separate single-use disposable unit dose cassette pre-loaded with a single solid UVI and a reusable handheld spring-powered actuator. The benefits include assured consistency with dosing, better product stability and ease of use as well as the potential to minimize vaccination pain and stress, and to eliminate needle disposal and needle stick injuries.

Farshad Guirakhoo, PhD, GeoVax’s chief scientific officer, said, “We are delighted to begin this collaboration with Enesi Pharma, as we believe their technology has the potential to revolutionize needle-free vaccine delivery for multiple indications in key global markets. The combination of our thermally stable vaccines with Enesi’s ImplaVax® needle-free device is a natural fit and we think there is significant scientific rationale for expecting success especially in resource constrained countries where cold chain storage is an issue.”

David Hipkiss, chief executive officer of Enesi Pharma, said “Our novel ImplaVax® technology has great potential for developing the next generation of vaccine products for infectious diseases and allergies. We have been impressed with the GeoVax MVA-VLP vaccine platform and feel that when taken together makes an excellent potential combination. We look forward to working with GeoVax on this exciting new project.”

Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies. You can obtain detailed information about the use of cookies on our website by clicking on "More information”.